JP2005516581A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516581A5
JP2005516581A5 JP2002589641A JP2002589641A JP2005516581A5 JP 2005516581 A5 JP2005516581 A5 JP 2005516581A5 JP 2002589641 A JP2002589641 A JP 2002589641A JP 2002589641 A JP2002589641 A JP 2002589641A JP 2005516581 A5 JP2005516581 A5 JP 2005516581A5
Authority
JP
Japan
Prior art keywords
cell
cells
present
epitope
cell epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002589641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015341 external-priority patent/WO2002092773A2/en
Publication of JP2005516581A publication Critical patent/JP2005516581A/ja
Publication of JP2005516581A5 publication Critical patent/JP2005516581A5/ja
Pending legal-status Critical Current

Links

JP2002589641A 2001-05-15 2002-05-13 自己免疫およびアレルギー疾患を処置するための非−腫瘍抗原に特異的な細胞傷害性リンパ球を生産するためのエクス−ビボプライミング Pending JP2005516581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29130001P 2001-05-15 2001-05-15
PCT/US2002/015341 WO2002092773A2 (en) 2001-05-15 2002-05-13 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009062554A Division JP5247547B2 (ja) 2001-05-15 2009-03-16 自己免疫およびアレルギー疾患を処置するための非腫瘍抗原に特異的な細胞傷害性リンパ球

Publications (2)

Publication Number Publication Date
JP2005516581A JP2005516581A (ja) 2005-06-09
JP2005516581A5 true JP2005516581A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=23119750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002589641A Pending JP2005516581A (ja) 2001-05-15 2002-05-13 自己免疫およびアレルギー疾患を処置するための非−腫瘍抗原に特異的な細胞傷害性リンパ球を生産するためのエクス−ビボプライミング
JP2009062554A Expired - Fee Related JP5247547B2 (ja) 2001-05-15 2009-03-16 自己免疫およびアレルギー疾患を処置するための非腫瘍抗原に特異的な細胞傷害性リンパ球

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009062554A Expired - Fee Related JP5247547B2 (ja) 2001-05-15 2009-03-16 自己免疫およびアレルギー疾患を処置するための非腫瘍抗原に特異的な細胞傷害性リンパ球

Country Status (11)

Country Link
US (10) US7811816B2 (cg-RX-API-DMAC10.html)
EP (4) EP2107110A3 (cg-RX-API-DMAC10.html)
JP (2) JP2005516581A (cg-RX-API-DMAC10.html)
AT (1) ATE438710T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002308732A1 (cg-RX-API-DMAC10.html)
CA (1) CA2447593C (cg-RX-API-DMAC10.html)
DE (1) DE60233231D1 (cg-RX-API-DMAC10.html)
ES (1) ES2329453T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA03010507A (cg-RX-API-DMAC10.html)
PT (1) PT1407004E (cg-RX-API-DMAC10.html)
WO (1) WO2002092773A2 (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE438710T1 (de) * 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
WO2003015716A2 (en) * 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
JP2007509063A (ja) * 2003-10-17 2007-04-12 ベイラー　カレッジ　オブ　メディスン Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2011031757A1 (en) * 2009-09-11 2011-03-17 Centocor Ortho Biotech Inc. Serum markers for identification of cutaneous systemic sclerosis subjects
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
EP2365036A1 (en) * 2010-03-12 2011-09-14 Cytec Surface Specialties, S.A. Radiation curable aqueous coating compositions
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
LU91934B1 (en) * 2012-01-25 2013-07-26 Ct De Rech Public Gabriel Lippmann Controlled radical assisted polymerization
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
US12188004B2 (en) * 2012-05-08 2025-01-07 The Johns Hopkins University Cancer immunotherapy using transfusions of allogeneic, tumor-specific CD4+ T cells
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
US9848587B2 (en) 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US10702226B2 (en) 2015-08-06 2020-07-07 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
US10716525B2 (en) 2015-08-06 2020-07-21 Covidien Lp System and method for navigating to target and performing procedure on target utilizing fluoroscopic-based local three dimensional volume reconstruction
US10674982B2 (en) 2015-08-06 2020-06-09 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
US11529190B2 (en) 2017-01-30 2022-12-20 Covidien Lp Enhanced ablation and visualization techniques for percutaneous surgical procedures
US11793579B2 (en) 2017-02-22 2023-10-24 Covidien Lp Integration of multiple data sources for localization and navigation
AU2018283319B2 (en) * 2017-06-16 2023-11-09 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses
US10699448B2 (en) 2017-06-29 2020-06-30 Covidien Lp System and method for identifying, marking and navigating to a target using real time two dimensional fluoroscopic data
US10893843B2 (en) 2017-10-10 2021-01-19 Covidien Lp System and method for identifying and marking a target in a fluoroscopic three-dimensional reconstruction
US11364004B2 (en) 2018-02-08 2022-06-21 Covidien Lp System and method for pose estimation of an imaging device and for determining the location of a medical device with respect to a target
US11705238B2 (en) 2018-07-26 2023-07-18 Covidien Lp Systems and methods for providing assistance during surgery
US11877806B2 (en) 2018-12-06 2024-01-23 Covidien Lp Deformable registration of computer-generated airway models to airway trees
US11617493B2 (en) 2018-12-13 2023-04-04 Covidien Lp Thoracic imaging, distance measuring, surgical awareness, and notification system and method
US11801113B2 (en) 2018-12-13 2023-10-31 Covidien Lp Thoracic imaging, distance measuring, and notification system and method
US11357593B2 (en) 2019-01-10 2022-06-14 Covidien Lp Endoscopic imaging with augmented parallax
US11625825B2 (en) 2019-01-30 2023-04-11 Covidien Lp Method for displaying tumor location within endoscopic images
US11744643B2 (en) 2019-02-04 2023-09-05 Covidien Lp Systems and methods facilitating pre-operative prediction of post-operative tissue function
US11627924B2 (en) 2019-09-24 2023-04-18 Covidien Lp Systems and methods for image-guided navigation of percutaneously-inserted devices
US12102298B2 (en) 2019-12-10 2024-10-01 Covidien Lp Lymphatic system tracking
CN111944018B (zh) * 2020-08-28 2022-12-23 深圳市乐土生物医药有限公司 诱导肝癌特异性细胞毒性t淋巴细胞的抗原多肽及其应用
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614611A (en) * 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5645837A (en) * 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
AU5801896A (en) * 1995-05-23 1996-12-11 Scripps Research Institute, The Antigen-specific activation of unprimed cd8+ t cells
JP2001503260A (ja) * 1996-10-23 2001-03-13 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 改良されたワクチン
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
DE69942100D1 (de) * 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
EP1330263A2 (en) * 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
ATE438710T1 (de) * 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
WO2003015716A2 (en) * 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof

Similar Documents

Publication Publication Date Title
Poggi et al. Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment
Chaudhary et al. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting
JP2023531989A5 (cg-RX-API-DMAC10.html)
JP2023531990A5 (cg-RX-API-DMAC10.html)
JP2023531991A5 (cg-RX-API-DMAC10.html)
Snook et al. Sphingolipid-binding proteins
ES2657443T3 (es) Anticuerpos anti-GITR y usos de los mismos
JP2023052777A5 (cg-RX-API-DMAC10.html)
IL266221B1 (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
JP2006511196A5 (cg-RX-API-DMAC10.html)
JP2014530009A5 (cg-RX-API-DMAC10.html)
JP2004531270A5 (cg-RX-API-DMAC10.html)
JP2004536332A5 (cg-RX-API-DMAC10.html)
JP2003531578A5 (cg-RX-API-DMAC10.html)
JP2006523595A5 (cg-RX-API-DMAC10.html)
JP2004535402A5 (cg-RX-API-DMAC10.html)
TW200732346A (en) Chimeric hepatitis C virus antigens for eliciting an immune response
WO2007041171A3 (en) Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
Doeden et al. Hydroa‐like lymphoma with CD56 expression
WO2003038062A3 (en) Generation of use of tc1 and tc2 cells
WO2004102198A3 (en) Selection of b cells with specificity of interest: method of preparation and use
Jayant et al. Immunological basis of genesis of hepatocellular carcinoma: Unique challenges and potential opportunities through immunomodulation
Foroughi et al. Polymer-induced heteronucleation for protein single crystal growth: structural elucidation of bovine liver catalase and concanavalin A forms
JP2005034154A5 (cg-RX-API-DMAC10.html)
JP2004503217A5 (cg-RX-API-DMAC10.html)